NewsAI-assisted

Biocon Announces Mukesh Kamath As Interim CFO During Crucial Financial Period

Biocon appoints Mukesh Kamath as Interim CFO starting June 11, 2024. Kamath brings extensive finance experience from his 20-year tenure at Biocon.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Jun 13, 2024Updated Jun 26, 2025 · 2 min read
Share
Biocon Announces Mukesh Kamath As Interim CFO During Crucial Financial Period
https://www.livemint.com/companies/news/serum-arm-to-double-investment-in-biocon-unit-11682444967652.html
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Biocon has announced that Mukesh Kamath is appointed as the new Interim Chief Financial Officer and Key Managerial Personnel, starting on June 11, 2024. Kamath currently holds the position of Head of Business Finance R&D and is also responsible for overseeing indirect taxation, capital expenditure, and various other finance-related functions.

Mukesh Kamath has been with Biocon since 2004, starting as a Management Executive and working in all finance-related areas within the Biocon Group. Mr. Kamath brings a wealth of experience to his new role, having served as Biocon's Deputy CFO for the past five years. His tenure at Biocon has been marked by significant contributions to financial planning, treasury management, and investor relations.

Before his time at Biocon, he held various positions at Infodesk Manipal, United Breweries, and Techsar Technologies. Kamath is a Chartered Accountant, accredited by the Institute of Chartered Accountants of India. For further updates on Biocon's financial developments and strategic initiatives, stakeholders are encouraged to monitor the company's official communications and regulatory filings.

 

 

 

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →